ReviewAdvances in therapy2017
A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids.
Review in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Effects of dietary n-6/n-3 PUFA ratio on growth performance and lipid metabolism in nursery pigs.Frontiers in veterinary science · 2025Article
- A Case of Diabetic Ketoacidosis With Severe Hypertriglyceridemia and Slowly Resolving Metabolic Acidosis.Cureus · 2024Article
- The Role of Omega- 3 Polyunsaturated Fatty Acids in Diabetes Mellitus Management: A Narrative Review.Current nutrition reports · 2024Review
- Treating Hypertriglyceridemia-Induced Pancreatitis With Intravenous Insulin and Plasmapheresis.Cureus · 2022Article
- Changes in Serum, Red Blood Cell, and Colonic Fatty Acids in a Personalized Omega-3 Fatty Acid Supplementation Trial.Nutrition and cancer · 2022Article
- Article
- Treatment of Dyslipidaemia in Children.Biomedicines · 2021Review
- Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids.Frontiers in nutrition · 2021Article
- Case Report: Management of a Patient With Chylomicronemia Syndrome During Pregnancy With Medical Nutrition Therapy.Frontiers in nutrition · 2021Article
- Article
- Diet and Nutraceutical Supplementation in Dyslipidemic Patients: First Results of an Italian Single Center Real-World Retrospective Analysis.Nutrients · 2020Article
- Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review.Current cardiology reviews · 2020Review
- Potentially modifiable blood triglyceride levels by the control of conventional risk factors.Lipids in health and disease · 2019Article
- Very Severe Hypertriglyceridemia in a Large US County Health Care System: Associated Conditions and Management.Journal of the Endocrine Society · 2019Article
- The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.Endocrine reviews · 2019Review
- The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Review
- Mapping the sites of the lipoprotein lipase (LPL)-angiopoietin-like protein 4 (ANGPTL4) interaction provides mechanistic insight into LPL inhibition.The Journal of biological chemistry · 2019Article
- The Role of Nutrients in Reducing the Risk for Noncommunicable Diseases during Aging.Nutrients · 2019Review
- Hypertriglyceridemia, an Underestimated Cardiovascular Risk Factor: An Epidemiological Study of the Rome Area.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Article
- Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids.Current atherosclerosis reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular (CV) disease remains the leading cause of preventable death in the US. Hyperlipidemia is a major modifiable risk factor for CV disease, and after numerous clinical trials have demonstrated that reductions in low-density lipoprotein (LDL) cholesterol with statin therapy can prevent major adverse CV events, statins have emerged as the drug of choice to lower LDL cholesterol and reduce CV risk. However, some statin-treated patients remain at high residual risk of CV events despite achieving low LDL cholesterol levels, especially if their triglyceride (TG) levels are elevated or their high-density lipoprotein (HDL) cholesterol levels low. Evidence from genetic and observational studies has linked elevated TG levels to an increased risk of CV events. Furthermore, very high TG levels are associated with acute pancreatitis. Consequently, several clinical practice guidelines provide recommendations for the management and treatment of high and very high TG levels. This review focuses on the clinical practice guidelines for the management of hypertriglyceridemia and the role of prescription omega-3 fatty acids in preventing pancreatitis and CV disease in individuals with high and very high TG levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.